Role of Adaptor Complex AP-3 in Targeting Wild-Type and Mutated CD63 to Lysosomes

Brian Rous, Barbara J. Reaves, Gudrun Ihrke, John A. G. Briggs, Stuart R. Gray, David Stephens, George Banting, J. Paul LuzioMolecular 2002 · DOI

TL;DR

This paper identifies a specific mutation in the CD63 protein's tail (GYEVI) that makes its lysosomal targeting strictly dependent on the AP-3 adaptor complex. This discovery provides a powerful tool to dissect the AP-3 pathway, revealing that it mediates a direct route from the trans-Golgi network (TGN) to lysosomes, bypassing early endosomes.

What Problem Does This Paper Address?

Cells meticulously sort and deliver proteins to their correct destinations. Lysosomes, the cell's recycling centers, require a specific set of integral membrane proteins. The precise mechanisms by which these proteins are targeted to lysosomes, especially from the trans-Golgi network (TGN), are complex and not fully understood. While tyrosine-based sorting motifs (like YXXØ) are known to be involved, and adaptor protein complexes (APs) like AP-1, AP-2, and AP-3 are implicated in intracellular trafficking, the specific roles of each AP in lysosomal targeting, particularly for proteins like CD63, remained unclear. This paper aims to elucidate the role of AP-3 in the lysosomal targeting of CD63, a tetraspanin protein known to reside in lysosomes.

Methods

The researchers employed a multi-pronged approach:

  • Yeast Two-Hybrid System: This was a core technique to investigate direct protein-protein interactions. They tested how different versions of the CD63 protein's tail sequence interacted with the μ subunits of various AP complexes (specifically μ2 and μ3). This allowed them to quantify the binding strength and specificity.
  • Cell Culture and Transfection: They used various cell lines (normal rat kidney - NRK, COS-7, NIH-3T3, and mutant cell lines like pearl and mocha mice, which have defects in AP-3 subunits) to express wild-type and mutated CD63 proteins.
  • Immunofluorescence Microscopy: This technique allowed them to visualize the cellular localization of the expressed CD63 proteins, often co-staining with markers for lysosomes (like LAMP-2) or other organelles (like TGN38) to determine where the protein ended up.
  • Fluorescence-Activated Cell Sorting (FACS): FACS was used to quantitatively assess the proportion of CD63 protein found on the cell surface versus intracellularly, providing a more precise measure of trafficking efficiency.
  • Chimeric Protein Construction: They created fusion proteins (e.g., CD8-CD63 and CD63-TGN38) to test whether specific domains of CD63 (cytosolic tail, lumenal/transmembrane domains) were sufficient for lysosomal targeting.
  • Chloroquine Treatment: This treatment disrupts endosomal acidification, causing proteins that traffic through early endosomes to accumulate there. This was used to differentiate between AP-3-dependent pathways that might bypass early endosomes and those that go through them.

Datasets

Not discussed in the paper. The study relies on established cell lines and the generation of recombinant DNA constructs.

Key Insights and Ideas

  • The GYEVI motif is a powerful AP-3 dependency marker: The mutation of the final 'M' in CD63's GYEVM tail to 'I' (resulting in GYEVI) dramatically shifted its lysosomal localization to the cell surface in AP-3 deficient cells. This created a "reporter" for AP-3 function.
  • AP-3 mediates a direct TGN-to-lysosome pathway: By using the GYEVI mutant, the researchers demonstrated that AP-3 facilitates a direct route from the TGN to lysosomes that bypasses early endosomes. This was evidenced by the GYEVI mutant not being trapped in early endosomes under chloroquine treatment, unlike proteins that do use this route.
  • Specificity of AP interactions is crucial: The GYEVI mutant showed strong interaction with μ3 (implicated in AP-3) but very weak interaction with μ2 (implicated in AP-2, involved in cell surface endocytosis). This explains why the mutant gets "stuck" on the surface in AP-3 deficient cells – it can't be efficiently internalized.
  • Wild-type CD63 uses multiple pathways: While the GYEVI mutant highlights the AP-3 pathway, wild-type CD63 appears to utilize both the AP-3-dependent direct route and a pathway involving the cell surface and early endosomes.

Key Results

  • The wild-type CD63 carboxyterminal tail (GYEVM) strongly interacts with the AP-3 subunit μ3 in yeast two-hybrid assays.
  • Mutations in the GYEVM motif that reduced μ3 interaction generally led to increased cell surface localization of CD63.
  • The GYEVI mutant of CD63 localized almost exclusively to the cell surface in AP-3 deficient cells (pearl and mocha mice) but to lysosomes in wild-type cells and rescued AP-3 deficient cells.
  • Wild-type CD63, but not the GYEVI mutant, showed some trapping in early endosomes upon chloroquine treatment, indicating that wild-type CD63 can use an early endosome-dependent pathway.
  • The CD63-TGN38 chimera, expected to traffic via early endosomes, was trapped in early endosomes upon chloroquine treatment, serving as a positive control for this pathway.

Limitations and Future Work

  • Evolutionary rationale for GYEVM vs. GYEVI: The paper ponders why wild-type CD63 uses the GYEVM motif, which is less efficient for AP-3 targeting, rather than the GYEVI motif. They hypothesize that the GYEVI mutant's poor interaction with μ2 might be detrimental if it were to accumulate on the cell surface, potentially impacting cell adhesion or migration functions. This suggests future work could explore the cell surface functions of CD63 and how its distribution is regulated.
  • Specificity of AP-3 subunits: While the study focuses on μ3, the precise roles of other AP-3 subunits (like δ) in this pathway could be further investigated.
  • In vivo relevance: While the study uses cell lines and mouse models, further in vivo studies could confirm these findings in more complex biological systems.
  • Other lysosomal proteins: The findings for CD63 could serve as a model to investigate the AP-3 dependency of other lysosomal proteins.

Summary updated

Abstract

CD63 is a lysosomal membrane protein that belongs to the tetraspanin family. Its carboxyterminal cytoplasmic tail sequence contains the lysosomal targeting motif GYEVM. Strong, tyrosine-dependent interaction of the wild-type carboxyterminal tail of CD63 with the AP-3 adaptor subunit mu 3 was observed using a yeast two-hybrid system. The strength of interaction of mutated tail sequences with mu 3 correlated with the degree of lysosomal localization of similarly mutated human CD63 molecules in stably transfected normal rat kidney cells. Mutated CD63 containing the cytosolic tail sequence GYEVI, which interacted strongly with mu 3 but not at all with mu 2 in the yeast two-hybrid system, localized to lysosomes in transfected normal rat kidney and NIH-3T3 cells. In contrast, it localized to the cell surface in transfected cells of pearl and mocha mice, which have genetic defects in genes encoding subunits of AP-3, but to lysosomes in functionally rescued mocha cells expressing the delta subunit of AP-3. Thus, AP-3 is absolutely required for the delivery of this mutated CD63 to lysosomes. Using this AP-3-dependent mutant of CD63, we have shown that AP-3 functions in membrane traffic from the trans-Golgi network to lysosomes via an intracellular route that appears to bypass early endosomes.
BibTeX
@inproceedings{rous2002role,
  author = {Brian Rous and Barbara J. Reaves and Gudrun Ihrke and John A. G. Briggs and Stuart R. Gray and David Stephens and George Banting and J. Paul Luzio},
  title = {{Role of Adaptor Complex AP-3 in Targeting Wild-Type and Mutated CD63 to Lysosomes}},
  booktitle = {Molecular},
  year = {2002},
  doi = {10.1091/mbc.01-08-0409},
}
Figure